Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia

Pediatric Blood & Cancer
Nicole LiberioMonica S Thakar

Abstract

Donor lymphocyte infusion (DLI) is often used to treat leukemic relapse after hematopoietic cell transplantation (HCT). However, the relationship between outcomes and distinct DLI cellular composition has not been previously reported. Additionally, there are limited published data on efficacy in pediatrics. We evaluated whether DLI cellular content and development of graft-versus-host disease (GVHD) impacted disease and influenced overall survival (OS) in children receiving DLI for recurrent leukemia. We performed an Institutional Review Board-approved, retrospective study investigating all consecutive DLIs given to patients at the Children's Hospital of Wisconsin between 1980 and 2018. Analyses were conducted using Mann-Whitney, Fisher exact, and chi-square tests. Thirty patients ≤20 years old with hematologic malignancies (myeloid [AML/MDS/CML/JMML], n = 23; lymphoid [ALL], n = 7) received DLI to treat post-transplant relapse. We found no significant difference in OS or development of GVHD based on CD3, CD4, CD8, CD56, or CD19 DLI cellular composition. With a median follow-up of 0.69 (range, 0.04-16.61) years, OS at five years was 32% ± 9%.  The lymphoid group had a five-year survival rate at 71% ± 17% compared with the myelo...Continue Reading

References

Oct 6, 2000·Bone Marrow Transplantation·R H CollinsP Parker
Mar 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Guliang XiaBryon D Johnson
Mar 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Carol Ann HuffRichard J Jones
Jun 11, 2009·Cancer Research·Patrick A Baeuerle, Carsten Reinhardt
Aug 25, 2012·Current Opinion in Hematology·Giacomo OliveiraChiara Bonini
Feb 7, 2013·Journal of Cancer·Jeanne M PalmerSubramaniam Malarkannan
Mar 26, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Merav BarMary E D Flowers
Feb 15, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marie BleakleyWarren Shlomchik
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Jul 24, 2015·European Journal of Immunology·Chiara Bonini, Anna Mondino
Dec 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arend von StackelbergLia Gore
Feb 22, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Toshihiro MiyamotoShin-Ichiro Mori
Nov 28, 2017·Current Opinion in Pediatrics·Jessica B Foster, Shannon L Maude
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Aug 29, 2018·Frontiers in Immunology·Alex M AbelSubramaniam Malarkannan
Mar 13, 2019·International Journal of Cancer. Journal International Du Cancer·Sarah OelsnerWinfried S Wels

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.